[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100338251":3},{"organization":4,"outcomesModule":7,"designInfo":52,"detailedDescription":16,"studyPopulation":16,"armGroups":58,"interventions":67,"overallOfficials":75,"centralContacts":79,"locations":86,"responsibleParty":191,"collaborators":16,"id":193,"slug":16,"hasResults":194,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":16,"eligibilityCriteria":198,"healthyVolunteers":194,"sex":199,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":16,"studyType":205,"phases":206,"briefSummary":208,"conditions":209,"keywords":16,"overallStatus":134,"whyStopped":16,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},{"fullName":5,"class":6},"CSL Behring","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage (%) of subjects with CIDP relapse in the Randomized Phase by dose level","CIDP relapse, defined as a clinical decline relative to the previous assessment as indicated by an increase in modified Rankin Scale (mRS) of ≥ 1 point, in the Randomized Phase","Approximately 24 weeks",[14,18,20,22,24,26,28,30,32,36,39,42,44,47,50],{"measure":15,"description":16,"timeFrame":17},"Percentage of subjects with treatment emergent adverse events (TEAEs) by dose level",null,"Approximately 56 weeks",{"measure":19,"description":16,"timeFrame":17},"Rate of TEAEs per infusion",{"measure":21,"description":16,"timeFrame":17},"Rate of mild, moderate, and severe TEAEs per infusion by dose level",{"measure":23,"description":16,"timeFrame":17},"Percentage of subjects with serious TEAEs",{"measure":25,"description":16,"timeFrame":17},"Rate of serious TEAEs per infusion",{"measure":27,"description":16,"timeFrame":17},"Percentage of subjects with related TEAEs",{"measure":29,"description":16,"timeFrame":17},"Rate of related TEAEs per infusion",{"measure":31,"description":16,"timeFrame":12},"Percentage of subjects with CIDP relapse in the Dose Exploration Phase by dose level assigned in the Randomized Phase",{"measure":33,"description":34,"timeFrame":35},"Change in modified Rankin Scale (mRS) score from baseline in the Randomized Phase","The mRS is a disability scale ranging from 0 (asymptomatic) to 6 (death)","Baseline and Approximately 24 weeks",{"measure":37,"description":38,"timeFrame":12},"Percentage (%) of subjects with CIDP improvement in the Randomization Phase by dose level","CIDP improvement in the Randomized Phase, defined as a decrease in mRS score ≥ 1 from previous visit",{"measure":40,"description":41,"timeFrame":12},"Percentage (%) of subjects with CIDP recovery in the Randomization Phase by dose level","CIDP recovery in the Randomized Phase, defined as decrease in mRS score as comparedto baseline AND mRS score of 1 or 0 at end of Randomized Phase",{"measure":43,"description":16,"timeFrame":12},"Time to CIDP relapse in Randomized Phase by dose level",{"measure":45,"description":46,"timeFrame":12},"Percentage (%) of subjects with CIDP improvement in the Dose Exploration Phase (DEP) by dose level","CIDP improvement in the Dose Exploration Phase, defined as decrease in mRS score ≥ 1 from baseline",{"measure":48,"description":49,"timeFrame":12},"Percentage (%) of subjects with CIDP recovery in the Dose Exploration Phase by dose level","CIDP recovery in the Dose Exploration Phase, defined as decrease in mRS score compared to baseline AND mRS score of 1 or 0 at end of DEP",{"measure":51,"description":16,"timeFrame":12},"Time to CIDP Relapse in the Dose Exploration Phase by dose level",{"allocation":53,"interventionModel":54,"interventionModelDescription":16,"primaryPurpose":55,"observationalModel":16,"timePerspective":16,"maskingInfo":56},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":57,"maskingDescription":16,"whoMasked":16},"NONE",[59,64],{"label":60,"type":61,"description":16,"interventionNames":62},"IgPro10 (dose level 1)","EXPERIMENTAL",[63],"Biological: IgPro10",{"label":65,"type":61,"description":16,"interventionNames":66},"IgPro10 (dose level 2)",[63],[68],{"type":69,"name":70,"description":71,"armGroupLabels":72,"otherNames":73},"BIOLOGICAL","IgPro10","Normal human immunoglobulin G administered intravenously",[60,65],[74],"Privigen",[76],{"name":77,"affiliation":5,"role":78},"Study Director","STUDY_DIRECTOR",[80],{"name":81,"role":82,"phone":83,"phoneExt":84,"email":85},"Trial Registration Coordinator","CONTACT","6108784697","+1","clinicaltrials@cslbehring.com",[87,101,112,122,132,146,156,168,178],{"facility":88,"status":89,"city":90,"state":91,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":100,"contacts":16},"Phoenix Children's Hospital","COMPLETED","Phoenix","Arizona","85016","United States","US",{"type":96,"coordinates":97},"Point",[98,99],-112.07404,33.44838,{"lat":99,"lon":98},{"facility":102,"status":103,"city":104,"state":105,"zip":106,"country":93,"countryCode":94,"cosmosGeoPoint":107,"geoPoint":111,"contacts":16},"Children's Hospital of Los Angeles","WITHDRAWN","Los Angeles","California","90027",{"type":96,"coordinates":108},[109,110],-118.24368,34.05223,{"lat":110,"lon":109},{"facility":113,"status":103,"city":114,"state":115,"zip":116,"country":93,"countryCode":94,"cosmosGeoPoint":117,"geoPoint":121,"contacts":16},"University of Iowa Hospitals and Clinics","Iowa City","Iowa","52242-1009",{"type":96,"coordinates":118},[119,120],-91.53017,41.66113,{"lat":120,"lon":119},{"facility":123,"status":103,"city":124,"state":125,"zip":126,"country":93,"countryCode":94,"cosmosGeoPoint":127,"geoPoint":131,"contacts":16},"Akron Children's Hospital","Akron","Ohio","44647",{"type":96,"coordinates":128},[129,130],-81.51901,41.08144,{"lat":130,"lon":129},{"facility":133,"status":134,"city":135,"state":136,"zip":137,"country":93,"countryCode":94,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Children's Hospital of Philadelphia","RECRUITING","Philadelphia","Pennsylvania","19104",{"type":96,"coordinates":139},[140,141],-75.16362,39.95238,{"lat":141,"lon":140},[144],{"name":145,"role":82,"phone":16,"phoneExt":16,"email":16},"Use Central Contact",{"facility":147,"status":103,"city":148,"state":149,"zip":150,"country":93,"countryCode":94,"cosmosGeoPoint":151,"geoPoint":155,"contacts":16},"Le Bonheur Children's Hospital","Memphis","Tennessee","38105",{"type":96,"coordinates":152},[153,154],-90.04898,35.14953,{"lat":154,"lon":153},{"facility":157,"status":134,"city":158,"state":159,"zip":160,"country":93,"countryCode":94,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Neurology Rare Disease Center","Flower Mound","Texas","75028",{"type":96,"coordinates":162},[163,164],-97.09696,33.01457,{"lat":164,"lon":163},[167],{"name":145,"role":82,"phone":16,"phoneExt":16,"email":16},{"facility":169,"status":89,"city":170,"state":171,"zip":172,"country":93,"countryCode":94,"cosmosGeoPoint":173,"geoPoint":177,"contacts":16},"Children's Specialty Group","Norfolk","Virginia","23507",{"type":96,"coordinates":174},[175,176],-76.28522,36.84681,{"lat":176,"lon":175},{"facility":179,"status":134,"city":180,"state":181,"zip":182,"country":93,"countryCode":94,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"Seattle Children's Hospital","Seattle","Washington","98105",{"type":96,"coordinates":184},[185,186],-122.33207,47.60621,{"lat":186,"lon":185},[189],{"name":190,"role":82,"phone":16,"phoneExt":16,"email":16},"Central Contact",{"type":192,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100338251",false,"NCT03684018","Two Dose Levels of Privigen in Pediatric CIDP","Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP","Inclusion Criteria:\n\n* \\- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.\n\nExclusion Criteria:\n\n* \\- Absence of CIDP symptoms\n* -History or family history of inherited neuropathy\n* -Diagnosed developmental delay or regression\n* -History of thrombotic episode\n* -Known or suspected hypersensitivity to Privigen\n* -Known allergic or other severe reactions to blood products\n* -Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study\n* -Pregnant or breastfeeding mother\"","ALL","2 Years","17 Years",{"count":203,"type":204},30,"ESTIMATED","INTERVENTIONAL",[207],"PHASE4","A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment",[210],"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","2026-05-28",{"date":213,"type":214},"2026-06-01","ACTUAL",{"date":216,"type":214},"2019-02-28",{"date":218,"type":204},"2029-12-20",{"name":5,"class":6},9]